Is the Cause of Mitral Regurgitation Relevant for MitraClip?

Mitral regurgitation (MR) is the most common valvulopathy: it is present in (at least) 7.5% of patients >75 years old.

This pathology can be classified as primary or degenerative MR (DMR) and secondary or functional MR (FMR).

 

FMR can be caused by dilatation of the left atrium (most often due to atrial fibrillation), occurring in 27% of cases (a-FMR), or by involvement of the ventricle, known as ventricular FMR (v-FMR).

Whether the MitraClip strategy is similar in these contexts is yet to be determined.

The analysis included a total of 1044 patients with MR. Among them, 423 had DMR and 621, FMR. Among the latter, 505 cases were v-FMR and 116, a-FMR.

The primary endpoint (PEP) was all-cause mortality and hospitalization due to heart failure at 2 years of follow-up.

The mean patient age was 76.3 years old; 40% of subjects were female and the Society of Thoracic Surgeons (STS) score was 8.6%.

Read also: Apixaban and Valve Thrombosis after TAVR.

Patients with v-FMR were younger, but had higher STS scores (9.3%). In the a-MRF group, there were more women and greater evidence of atrial fibrillation.

There were no differences in comorbidities nor in the New York Heart Association functional class.

In the echocardiographic findings, those with v-FMR had greater ejection fraction and larger ventricle diameters; those in the a-FMR group had a large left atrium and small ventricular diameters. In cases caused by DMF, the effective regurgitant orifice area was greater. No difference was observed as regards pressure in the pulmonary artery.

Read also: Mortality and Bleeding in Access Site Choice: Systematic Review.

There were no differences in procedure time, fluoroscopy time, or final outcome. Fewer clips were used in a-FMR patients.

The PEP was in favor of DMF compared with v-FMR and a-FMR (42.3% vs. 31.5% vs. 21.6%; p < 0.001), respectively.

Mortality was higher in those who presented a-FMR compared with DMR, and somewhat lower compared with those who presented v-FMR.

Read also: Can We Discharge TAVR Patients the Same Day?

The presence of tricuspid regurgitation was associated with higher mortality regardless of the cause of MR.

Conclusion

While procedural outcomes are excellent, patients with a-FMR and v-FMR have a worse clinical evolution than those with DMR.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes After Transcatheter Edge-to-Edge Mitral Valve Repair According to Mitral Regurgitation Etiology and Cardiac Remodeling

Reference: Sung-Han Yoon, et al. J Am Coll Cardiol Intv 2022;15:1711–1722.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

OPTION Trial: Left Atrial Appendage Closure

Atrial fibrillation ablation is a valid strategy. However, reoccurrence is frequent in these cases, often with asymptomatic presentation. Anticoagulation with warfarin has proven effective in...

TRI-SPA Study: Tricuspid Edge-to-Edge Treatment

Tricuspid regurgitation (TR) is a condition associated with high morbidity and mortality. Currently, surgery is the recommended treatment; however, it carries a high complication...

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...